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Despite significant improvements in lentivirus (LV) vector-based gene therapy there are still several safety
risks using LV vectors including the potential formation of replication-competent LV particles. To address
this shortcoming, we constructed a novel and safer gene transfer system using modifiedSIN-based LVgene
transfervectors.CentraltoourapproachisaconditionaldeletionoftheYpackagingsignalafterintegration
in the target genome. Here we demonstrate that after transduction of target cells, conventional SIN-based
LV transfer vectors can still be mobilized. However mobilization is rendered undetectable if transductions
are followed by a Cre/loxP-mediated excision of Y. Thus conditional elimination of the packaging signal
may represent another advance in increasing the safety of LV vectors for gene therapeutic treatment of
chronic diseases.
G
ammaretro (RV) - and lentivirus (LV) vectors are among the most advanced tools for the delivery of
therapeuticDNAintopatientcells
1,2.However,withthearrivalofvirus-basedgenetransfertechniquesin
clinical trials, numerous safety concerns have been raised after adverse effects have been observed in
laboratory animals and in patients treated with RV- and LV-modified cells
3. While reported adverse effects are
mainly due to insertional mutagenesis with resulting oncogene activation and clonal expansion, production of
replication-competent retroviruses (RCRs
4, remains a significant concern even after the development of self-
inactivating (SIN) transfer vector systems with LTR-based enhancer deletions
5. Specifically, Logan et al
6. noted
residual LTR-based promoter activity in a 293 derived cell line and cryptic low-level vector mobilization while
investigatingaSIN-based LVgene transfersystem.Sofar,nopracticalexamplefortheproduction ofreplication-
competent LV vectors (RCLs) have been described in clinical settings
7 yet this may be due to the relatively small
numbers of patients having received LV-based gene therapy. Possible scenarios of e.g. HIV-mediated LV mobil-
ization in a patient as a clinical pitfall of LV therapy have been simulated in vitro in gene-modified T cells
8.
Furthermore, RCRs have been found with components originating from endogenous retroviruses
9. The concern
of endogenous retroviruses being involved in the vector mobilization process has also been raised for LV vector
systems
10.ThusitisimportanttomaximizesafetyoftheLVgenetransfersystemwithrespecttocontrollingvector
molecule assembly in target cells.
To prevent inadvertent mobilization when using a LV gene transfer system, we designed LV vector genomes
with conditional presence of the required viral RNA packaging signal Y while still maintaining the established
SIN-based alterations that minimize activation of host genes in the periphery of the viral integration site.
Results
Functional LV vector particles after Y translocation into a cleavable loxP-flanked cassette. In order to evaluate
whether the change in the location of the HIV packaging signal would still allow for LV vector production we
designed a construct where Y was translocated into a cleavable loxP flanked cassette. The resulting transfer vector
was then compared to a construct of similar design with the native packaging signal (Fig. 1). Viral production was
carried out by transfection of 293T cells with these constructs 512 (LeGO-IG- mCherry- loxP-eGFP) or 521 (DY-
LeGO-IG-mCherry-loxP-Y-eGFP), plus co-transfected HIV helper constructs expressing Gag, Poland the VSV-G
envelope. FACS analyses of transduced reporter cells (HT1080) revealed successful transduction of recipient cells
with transfer vector 521, albeit at a 100 fold reduced titer when compared to the titer obtained in vector production
using the parental transfer vector construct 512 (data not shown).
Development of a transient packaging cell line containing HIV based vector components. Our next objective
wastoestablishatransient293TpackagingcelllinecontainingatleastoneLVtransfervectorgenomewitheither
the deleted Y (via vector 521) or the native counterpart (via vector 512). To accomplish this task, transduced
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1 target cells were enriched by sorting: the cell populations
transduced with authentic LV transfer vector genome indicated by
their double GFP and mCherry positive phenotype reached similar
levelsof68.0%(LV512,Fig.2A,uppermiddlepanel)and69.7%(LV
521, Fig. 2 A, upper right panel). The sorted GFP
1 cell populations
were subsequently transfected with a Cre expression plasmid
(pCMV-Shuttle-Cre). Cre mediated deletions of the loxP cassettes
in cells transduced with vectors 512 or 521
11,12 resulted in the con-
comitant deletion of GFP but not mCherry. Thus we monitored
fluorescent reporter gene expression on day two and five post tran-
sfection. After the fifth day, approximately 20 % 293T LV 512 and
12% 293T LV 521 of the mCherry/GFP double positive cells had
converted to a GFP-deficient phenotype (Fig. 2, compare per-
centage of GFP-negative populations in the left part of the upper
histograms (‘‘2 Cre’’) with the percentage of GFP-negative popu-
lationsintheleftpartofthelowerhistograms(‘‘1Cre’’).TheseGFP-
negative but still mCherry-positive cells were again enriched by cell
sorting (Fig. 2 B). Consequently producer cells containing the 521
transfer vector no longer contain either Y or GFP while producer
cells with the transfer vector 512 only lost the GFP gene.
LV vector production with cells containing HIV-based vector
components. In order to determine whether producer cells already
containing an integrated SIN - modified LV transfer vector could inad-
vertently mobilize this LV genome during packaging and if a con-
comitant deletion of Y could abrogate this potential mobilization, we
performed transient transfections utilizing 293T LV-521 and 293T LV-
512 modified producer cells. Specifically, the GFP negative, mCherry
positive 293T LV-512 and 293T LV-521 cells were transfected with HIV
Gag, Pol and VSV-G envelope helper plasmids and a titration series of a
transfer vector construct 528 containing a BFP fluorescent tag. Two
days post transfection supernatants were harvested by centrifugation
and HT1080 reporter cells were transduced with equal volumes of the
producer cell supernatants. Three days post transduction the recipient
HT1080 cells were then analysed for BFP and mCherry reporter gene
expression (Fig. 3). As expected HT1080 target cells transduced with
suboptimal amounts of the BFP encoded transfer vector (Fig. 3 B–E)
yielded a progressively lower number of BFP-positive cells when
compared to cells transduced with supernatants obtained from vector
productions carried out under optimal conditions (Fig. 3A). However,
under suboptimal concentrations of the transfer vector construct 528,
we were also able to detect a low percentage of mCherry positive BFP
negative cells within the HT1080 pool containing viral vector pre-
parations from the supernatant of 293T LV-512. These single positive
mCherry cells however were not detectable in the HT1080 pool
transduced with the supernatant from 293T LV-521 cells (deleted Y)
under the same conditions, thus providing evidence of abrogated
mobilization.
In order to exclude the possibility that these presumed HT1080
reporter cells may actually represent mCherry positive 293T pro-
ducer cells, single mCherry-positive cells transduced with the 293T
LV-512 supernatant (containing Y) were FACS-selected and pooled
(Supplemental Fig. S1).After limiting celldilution weexpanded four
positive for mCherry expression. We observed clonal LV insertions
by LAM-PCR
13 with at least three distinct integration profiles
(Supplemental Fig. S1 and S2a). These data provide direct evidence
that that these cells must have been transduced by cryptically acti-
vatedLVSINmCherrytransfervectorswithinthe293TLV-512cells.
In order to assure that the analyzed clones represent indeed HT1080
reporter cells and not 293T LV-512 cells carried over during the
transduction process, we also evaluated these cell clones for their
lack of adenoviral DNA detectable in 293T
14, but not in HT1080
genomic DNA. For reference, we selected a GAPDH DNA fragment
which was detectable by PCR in all genomic DNA samples.
Adenoviral DNA was not amplifiable in any of our analysed clones.
Thus, these data also support our assertion that the isolated clones
are of HT1080 and not 293T origin (Supplemental Fig. S2b).
Since FACS analyses with HT1080 cells transduced with the super-
natant of 293T LV-521 cells provided no evidence of mCherry-pos-
itive viral particles (Fig. 2), data directly support the premise that
deleting the packaging signal after successful transfer into target cells
can substantially increase the safety of LV vector-based gene delivery.
Discussion
In order to guard against potential LVvector mobilization as aresult
of RCL formation we improved the safety of the SIN-based LV gene
deliverysystembyallowingforconditionaldeletionofthepackaging
signal Y. Here we moved Y further downstream between the loxP
sites and immediately adjacent to a GFP reporter gene. This manip-
ulation allows for a conditional removal of Y after delivery of the
vector into recipient cells that can be monitored by the concomitant
lossof GFP. Toour knowledge thesedata are thefirstdemonstration
that upon removal of Y within the recipient genome cryptic vector
mobilization can be abrogated.
Our initial goal was to investigate if inadvertent mobilization of
lentiviral vectors would be detectable in 293T cells, commonly used
toproduceviralvectorparticles.Ourdatasupportearlierfindingsby
Logan and coworkers
6 that SIN-based transfer vectors can undergo
cryptic mobilization in the presence of LV helper constructs. These
findingsareofgreatconcernasrecent retroviralgenetherapyendea-
vors favor the use of LV vectors. The use of third generation helper
plasmids
15 during LV vector production addresses a safety concern
for separation of viral helper genes in order to reduce the risk of the
development of replication-competent LVs. The use of SIN-based
transfer vectors for LV transductions reduces the risk of undesired
geneactivationinthevicinityoftheviralintegrationsite.However,if
anintegratedviralvectorcanstillbemobilized,additionalinsertional
and putatively mutagenic events may occur following vector activa-
tion and packaging into capsids provided by either possible endo-
genous retroviruses or unrelated pathogenic viral infections. Pheno-
typicmixing
16iswellknownandutilizedwhenpseudotypingRVand
LV vectors with VSV-G for example. Thus our aim was to eliminate
the possibility of vector mobilization and viral dissemination by
deleting the LV packaging signal Y following a Cre/loxP mediated
excision in SIN-DY-LVs after successful gene transfer into recipient
cells.InadditiontorenderingLVvectorintegrationsmorestableina
clinical setting, deletions encompassing Y would also allow for safer
manipulation from a bioengineering perspective. For example, LV
helper constructs could be introduced into the cellular genome of
producer cells and optimized for expression without concomitant
concern of RCL formation.
Figure 1 | Structure of the double fluorescent lentivirus vectors analysed
in this study: The LV vectors 512 and 521 contain SIN long terminal
repeats (LTR), the packaging signal Y, a LV cis-acting region (CAR), an
EF1a(short) promoter (EF1a) drivingexpression of anmCherry reporter
gene, and an SFFV promoter (SFFV) together with an internal ribosome
entry site (IRES) driving expression of a GFP reporter gene. The
woodchuck hepatitis virus post transcriptional regulatory element (w) is
also indicated.
www.nature.com/scientificreports
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target cells. Thismanipulationalso opens thepossibility of therapeutic
cell expansion by coupling Y with homeobox transcription factors.
HoxB4 for instance, a potential candidate for therapeutic stem cell
expansion, could be used with hematopoietic stem and progenitor
cells in a clinical setting
17 and with this vector system. Since constitu-
tive expression of HoxB4 is associated with leukemia
18,19,a nin vitro
strategy to simultaneously delete HoxB4 and Y after gene transfer and
successful cell expansion could be of great therapeutic potential.
Several concerns will still have to be addressed before the above
‘proofofprinciple’experimentscanbeimplementedingenetherapy.
One concern is the observed reduced titer in our study after trans-
location of the packaging signal Y. While this could be a con-
sequence of spontaneous sequence deletions flanked by repetitive
loxP elements encompassing Y during virus production, it seems
unlikely since the region of homology is only 34 bp and our cell
population with dual fluorescent tags remained stable in the absence
of Cre. Another possibility for the reduced titer is a positional effect
duetothetranslocationofY
20–22.Thuswearecurrentlyinvestigating
viraltiteryieldsaftermovingtheloxPcleavagecassettecontainingY
closer to its native locus. A second concern to be addressed is the
reported potential low frequency carcinogenesis due to chromo-
somal rearrangements after implementation of the cre/loxP system
in cells with two or more integrants
23,24. Thus, for clinical trials,
careful screening for single integration events and/or the absence
of chromosomal rearrangements would be required prior to reintro-
ducing the therapeutic construct into a patient. Alternatively, imple-
mentation of a conditional ‘suicide gene’ may also serve as a
safeguard with implementation of the above cre/lox system.
Methods
Cloning procedures. All PCR-based cloning and analytic procedures were carried
out using Platinum Taq polymerase (Invitrogen, Carlsbad, CA). Primers were
purchased from Integrated DNA Technologies Inc. (IDT, Coralville, IA). Restriction
Figure 2 |(a)ExcisionofYvialoxPsitesmonitoredbydisappearanceofGFPreportergeneexpression.293TcellstransducedwithLV512(uppermiddle
panel) and LV 521 (upper right panel), respectively, were transfected with pCMV-Shuttle-Cre and analyzed for GFP and mCherry reporter gene
expression six days post transfection (lower panels, left: 293T LV 512, right 293T LV 521). (b) Cre-loxP-treated enriched cell populations after
transfection with pCMV-Shuttle-Cre. Left: 293T-LV 512, right: 293T-LV 521.
www.nature.com/scientificreports
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New England Biolabs (NEB, Ipswich, MA), respectively.
Construction of double fluorescent LV vectors with Y translocation into a
removable cassette. As a basis for our experiments we selected pLeGO-iG-SFFV-
IRES-eGFP (a generous gift of Dr. Kristoffer Weber, University Medical Center
Hamburg, Germany), in which an SFFV promoter – MCS – IRES - GFP expression
cassette is flanked by loxP
25. We modified this LV gene transfer system by inserting a
second fluorescent reporter gene, mCherry driven by the Elongation Factor 1a
(EF1a) promoter as follows: A 8144 bp HpaI XhoI fragment from pLeGO-iG-SFFV-
IRES-eGFP was recombined with an 1140 bp HpaI-SalI fragment from pWPT-
mCherry. Plasmid pWPT-mCherry was derived from a BamHI, SalI substitution of
GFP in pWPT-GFP containing the EF 1a promoter with mCherry from pRSC-PCh-
W resulting in LeGO-IG- mCherry- loxP-eGFP or construct 512 (Fig. 1A). A DNA
fragmentencodingtheHIVpackagingsignalYwasamplifiedwithconstruct512asa
template using primers HIV Y sense (59- CCCGCTAGCTCGACGCAGGACT-
CGGCTTGC-39) and HIV Y anti (59- CCCGCTAGCCTCCCCCGCTTAATAC-
TGACG-39) and Platinum Taq polymerase under the following cycling conditions:
40cycleswith95uC300,51.3uC300,72uC600.The156 bpampliconwasdigestedwith
NheI and transferred into the NheI site of construct 512 located between the 59 loxP
site and the SFFV promoter leading to construct 512-Y-shift. Deletion of the native
HIV Y signal in p512-Y-shift was performed as follows: A PCR fragment encoding
for the CMV promoter and the RU5 region but lacking the packaging signal Y was
generated with construct 512 as template using primers Y-del-sense (59-TGCTTA-
GGGTTAGGCGTTTTGCGCTGCTTC-39) and Y-del-anti (59-GCGCGCTCTTC-
CTCTATCCCTTTCGCTTTCAAGTCC -39) with Platinum Taq polymerase
(Invitrogen). at 35 cycles with 95uC for 300,5 0 uC for 300 and 29 at 72uC. After
digestion with NruI and SfoI the PCR fragment was substituted for a 1003 bp NruI
flankedfragmentinconstruct512leadingtoDY-LeGO-IG-mCherry-loxP-Y-eGFP
or construct 521 (Fig. 1B). Sequence integrity for all sequence manipulations was
verified by standard sequence analysis (Sequencing facility FHCRC, Seattle).
Construction of the Cre expression plasmid pCMV-Shuttle-Cre. Adenovirus 5
encoding Cre Recombinase (Ad-Cre, Eton Bioscience Inc., San Diego, CA) was
utilized as DNA template to amplify the Cre recombinase DNA fragment with
standard PCR amplification conditions using primers pShuttle-Cre-59 (59-
AGATCTGCCACCATGTCCAATTTACTGACCGTACAC-39) and pShuttle-Cre-39
(59-GTCGACTAATCGCCATCTTCCAGCA-39). The resulting PCR product was
subcloned into pCR2.1 (Clontech, Mountain View, CA) for sequence analysis
(Sequencing facility FHCRC, Seattle) and transferred into BglII, SalI digested
pShuttle-CMV
26 (Addgene, Cambridge, MA).
Construction of the BFP LV vector plasmid. Plasmid pRSCPBw was obtained by
substituting the 722 bpblue fluoresecent protein gene (BFP)cassette flanked byAgeI
and SalI sites from pCVL.Sce.IRES.mTagBFP (a kind gift from Dr. Andrew
Scharenberg, Seattle Children’s Research Institute, Seattle, WA, USA) for the GFP
cassette in pRRLsin.cPPT.hPGK.GFP.Wpre
29.
Tissue culture, vector production, transduction and fluorescent reporter gene
analysis. Human embryonic kidney 293T (HEK 293T
27 and HT1080 cells
28 were
cultivated in 10% FCS (Invitrogen) and DMEM (Invitrogen) with penicillin/
streptomycin solution (Invitrogen) at 37uC and 5%CO2in a humidified atmosphere.
LV vector production and was carried out according to previously published
procedures
29.For viral vectortransduction, unwanted HEK293T producer cells were
removed by centrifugation at 1200 x g. Supernatants were applied onto HT1080
reporter cells. FACS analyses of cells expressing fluorescent reporter genes were
performed on an LSR-II flow cytometer (Becton Dickinson, BD, San Jose, CA) and
resulting data were analyzed with FLOJO flow cytometry analysis software (FLOJO,
Ashland, OR). Sorting of fluorescent cells was performed with an ARIA II cell sorter
(Becton Dickinson).
Analytical PCR to discriminate between 293T producer cells and HT1080 target
cells. For PCR analysis of transduced HT1080 cells primers Adeno-sense (59-
GGTTTACTGGCCCCAATTTT-39) and Adeno-anti(59-
CACAGCCACGCTTTTCACTA-39) were used to detect a 304 bp fragment specific
for adenoviral DNA found in 293T cells but not HT1080 cells. For reference primers
GAPDH sense (59-CATCACTGCCACCCAGAA-39) and GAPDH anti (59-
GGGCCATGAGGTCCACCA-39) were utilized to detect a 552 bp Glyceraldehyde-
3-phosphate dehydrogenase gene (GAPDH) PCR fragment. Both primer sets were
addedto300 ngofgenomicDNAandamplifiedwithAmpliTaqGoldunderstandard
PCR conditions (32 cycles with 95uC for 150,6 2 uCf o r2 0 0 and 79 at 72uC).
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